Product Description
ALTU-238 is a long-acting subcutaneous formulation of recombinant human growth hormone, in a ready-to-use liquid suspension formulation, that employs Altus' proprietary protein crystallization and formulation technology. (Sourced from: http://www.altus.com; https://www.fiercebiotech.com/biotech/press-release-altus-pharmaceuticals-reacquires-altu-238-global-development-and)
Mechanisms of Action:
Novel Mechanism: No
Modality: Coagulation Factor
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Altus
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Hypopituitarism|Dwarfism, Pituitary
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00297713 |
NCT00297713 | P2 |
Completed |
Hypopituitarism|Dwarfism, Pituitary |
None |
2019-03-21 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|